SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Gracell Biotechnologies Inc. (GRCL) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($6.00, 41.5%).
- Analyst consensus target $6.00 (-41.5% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 25/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GRCL
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-28.25
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$6.00 (-41.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-15.35 |
$0.00 |
$-60.79M |
- |
| 2019 |
$-33.35 |
$0.00 |
$-132.18M |
- |
| 2020 |
$-15.05 |
$0.00 |
$-197.16M |
- |
| 2021 |
$-35.40 |
$366K |
$-465.88M |
-127289.6% |
| 2022 |
$-28.25 |
$0.00 |
$-607.51M |
- |
